Resseptor Therapeutics enhances the treatment of the immune system's ability to identify and respond to tissues, malignancies, and pathogens
Resseptor Therapeutics has raised $1.5M in total funding. The most recent round was Seed. The last funding was announced in May 2023.
Resseptor Therapeutics's investors include IP Group Australia.
Resseptor Therapeutics is headquartered in Melbourne, Australia.
Resseptor Therapeutics enhances the treatment of the immune system's ability to identify and respond to tissues, malignancies, and pathogens
Resseptor Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Resseptor Therapeutics — Funding & Investors." VCBacked, May 24, 2023, https://www.vcbacked.co/company/resseptor-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Resseptor Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/resseptor-therapeutics
{{cite web |title=Resseptor Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/resseptor-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated